Smith & Nephew PLC

Most Recent

  • uploads///recommendations
    Earnings Report

    Stryker: Analysts’ Recommendations before Its 3Q17 Earnings

    Stryker (SYK), the second-largest orthopedic device developer, is set to announce its 3Q17 earnings results on October 26, 2017.

    By Sarah Collins
  • uploads///RECONSTRUCTUVE MARKET POSITION
    Company & Industry Overviews

    What Zimmer Biomet’s Progress II Study Success Could Mean

    On December 22, 2017, Zimmer Biomet Holdings (ZBH) published the results of its Progress II trial, and the results were positive.

    By Sarah Collins
  • uploads///attune system
    Company & Industry Overviews

    How JNJ Aims to Regain Its Position in the Knee Implant Business

    Johnson & Johnson (JNJ) is the third-largest player in the global knee implant market and the second-largest player in markets outside the United States.

    By Sarah Collins
  • uploads///acclarent aera
    Company & Industry Overviews

    Johnson & Johnson’s Acclarent Aera Balloon Dilation System

    On February 27, 2018, Johnson & Johnson’s subsidiary Acclarent announced FDA approval for the expanded indication for Acclarent Aera.

    By Sarah Collins
  • uploads///Orthopedic medical devices
    Company & Industry Overviews

    How JNJ’s Orthopedic Medical Devices Performed in 4Q17 and 2017

    In 4Q17, Johnson & Johnson’s (JNJ) hip medical devices business generated revenue of $364 million.

    By Daniel Collins
  • uploads///acquisitions
    Company & Industry Overviews

    Stryker’s Inorganic Growth Strategy Continues to Boost Growth

    Stryker’s acquisition-driven growth strategy Stryker (SYK) has been growing at a fast pace through inorganic growth. It has undertaken a number of strategic acquisitions recently. In 3Q17, acquisitions contributed approximately 0.6% of the company’s YoY (year-over-year) sales growth, and in the first three quarters of 2017, Stryker acquisitions contributed ~3.2% of the company’s sales growth […]

    By Sarah Collins
  • uploads///risks
    Company & Industry Overviews

    Stryker and Zimmer Biomet Holdings Settled a Trade Secret Case

    On November 28, 2017, Howmedica Osteonics, an orthopedics subsidiary of Stryker (SYK) and Zimmer Biomet Holdings (ZBH), settled a trade secret case.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    What’s behind Zimmer Biomet’s Recent Stock Downtrend?

    Zimmer Biomet Holdings (ZBH) ended trading at $108.70 on November 7, 2017. Currently, ZBH stock’s 50-day moving average stands at $117.60.

    By Sarah Collins
  • uploads///GLOBAL FOOTPRINTS
    Company & Industry Overviews

    Asia-Pacific Still Zimmer Biomet’s Strongest Geography

    Zimmer Biomet Holdings witnessed a strong performance in its Asia-Pacific region. It contributed 16% to the company’s total sales.

    By Sarah Collins
  • uploads///mako
    Earnings Report

    How Mako Robots Are Driving Stryker’s Sales in 2017

    Mako sales in 3Q17 In 3Q17, Stryker sold 33 Mako robots, compared with 30 robots in 3Q16. In 2Q17, Stryker installed 26 Mako robots. Of these 33 robots, 23 were installed in the United States. Around 40% of US sales are expected to be in competitive accounts. Stryker is training surgeons on its total knee application […]

    By Sarah Collins
  • uploads///knee market share
    Company & Industry Overviews

    ZBH’s Persona Partial Knee Launch Expands Knee Implant Portfolio

    On September 11, 2017, Zimmer Biomet Holdings (ZBH) announced the launch of its Persona Partial Knee System.

    By Sarah Collins
  • uploads///risks
    Company & Industry Overviews

    Stryker Won the Patent Case against Zimmer Biomet Holdings

    On July 12, 2017, a US district court judge increased the penalties to be paid by Zimmer Biomet Holdings to Stryker related to its patent infringement case.

    By Sarah Collins
  • uploads///revenues by segment
    Company & Industry Overviews

    Recent Product Launches Expand Stryker’s Orthopedics Business

    In 1Q17, Stryker (SYK) reported YoY growth of ~18.5%. One of the contributing factors its growth is the company’s innovative product portfolio.

    By Sarah Collins
  • uploads///KNEE MARKET SHARE
    Company & Industry Overviews

    Stryker’s MAKO Total Knee Implant: Robotics in Orthopedics

    In March 2017, Stryker (SYK) announced the commercial launch of its robotic-arm assisted total knee application to be used with its MAKO system.

    By Sarah Collins
  • uploads///mitg highlights
    Earnings Report

    What Drove Medtronic’s MITG Segment Growth?

    Medtronic (MDT) reported ~$7.9 billion in worldwide revenues in fiscal 4Q17.

    By Sarah Collins
  • uploads///careadvantage
    Company & Industry Overviews

    Inside the Latest Capability Advancement in Johnson & Johnson’s Orthopedics

    On January 9, JNJ’s Medical Device division announced its Orthopedic Episode of Care Approach, a data-driven program that will accelerate value-based care.

    By Sarah Collins
  • uploads///KNEE MARKET SHARE
    Company & Industry Overviews

    What Impacted Zimmer Biomet’s Reconstructive Segment?

    In 3Q16, Zimmer Biomet Holdings (ZBH) reported total sales of $1.83 billion. It represented YoY (year-over-year) constant currency growth of 3.5%.

    By Sarah Collins
  • uploads///MITG
    Earnings Report

    Here’s What’s Driving Medtronic’s MITG Segment

    Of Medtronic’s ~$7.3 billion in worldwide revenues in fiscal 2Q17, ~$2.5 billion came from Medtronic’s MITG segment, representing ~34% of the company’s total revenues.

    By Sarah Collins
  • uploads///hip market share
    Company & Industry Overviews

    Must-Know Details of Zimmer Biomet’s Clinical Graphics Acquisition

    On September 15, 2016, Zimmer Biomet Holdings (ZBH) announced the strategic acquisition of Clinical Graphics.

    By Sarah Collins
  • uploads///Portfolio Breakdown of the PRITX
    Consumer

    A Look at PRITX’s Portfolio Changes So Far in 2016

    PRITX aims to invest in established companies that are either headquartered outside of the United States or whose main businesses are carried out outside the United States.

    By David Ashworth
  • uploads///stryker sales mix
    Company & Industry Overviews

    How Stryker Plans to Leverage the Under-Tapped Europe Opportunity

    Europe represents a potential growth opportunity for Stryker, as the company currently has a low market share in Europe compared to other developed markets.

    By Sarah Collins
  • uploads///geographic segmentationn
    Company & Industry Overviews

    Discussing Stryker’s Expansion and Growth in Emerging Markets

    Stryker registered ~$2.8 billion in revenue in 2Q16. Around 72% of this was generated by its US business, and the remainder came from international sales.

    By Sarah Collins
  • uploads///integration
    Company & Industry Overviews

    Zimmer Biomet’s Realized Synergies, Market Position after Integration

    Zimmer Holdings acquired Biomet in June 2015 and formed Zimmer Biomet Holdings (ZBH). The acquisition established the combined company as the second-largest player in the orthopedics medical device market segment.

    By Sarah Collins
  • uploads///Portfolio Breakdown of the BIAHX
    Fund Managers

    Seeking Returns by Investing Mainly in European Equity Securities

    The Brown Advisory WMC Strategic European Equity Fund Investor Shares generally invests at least 80% of its net assets in European companies.

    By David Ashworth
  • Company & Industry Overviews

    Industrials and Discretionary Helped AEDAX in 1Q16

    AEDAX fell 0.9% in 1Q16. But it still ranked second best among the 12 funds in this review.

    By David Ashworth
  • uploads///KNEE MARKET SHARE
    Company & Industry Overviews

    Zimmer Biomet Faces Market Share Erosion in the Knee Implant Market

    Zimmer Biomet (ZBH) is the leading provider of knee implants in the United States. It has approximately 40% market share, followed by Stryker, Johnson & Johnson, and Smith & Nephew.

    By Sarah Collins
  • Company & Industry Overviews

    Solid Metrics Make BIAHX Less Volatile Than Peers

    From a NAV return standpoint, BIAHX stood third among its peers for the one-year period until March 15, 2016. Since the ECB announcement of stimulus measures, the fund is fifth.

    By David Ashworth
  • Company & Industry Overviews

    Does the MFS International Growth Fund Deserve Your Attention?

    The MFS International Growth Fund’s standard deviation, or the volatility of returns, in the one-year period until February 29 was 15.3%.

    By David Ashworth
  • Company & Industry Overviews

    BIAHX: Could It Be a Candidate for Your Shortlist?

    The Brown Advisory – WMC Strategic European Equity Fund (BIAHX) was managing assets worth $1.1 billion as of January 2016.

    By David Ashworth
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.